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(57) ABSTRACT
Methods and systems for calculating tissue oxygenation, e.g.,
oxygen saturation, in a target tissue are disclosed. In some
embodiments, the methods include: (a) directing incident
radiation to a target tissue and determining reflectance spectra
of the target tissue by measuring intensities of reflected radia-
tion from the target tissue at a plurality of radiation wave-
lengths; (b) correcting the measured intensities of the reflec-
tance spectra to reduce contributions thereto from skin and fat
layers through which the incident radiation propagates; (c)
determining oxygen saturation in the target tissue based on
the corrected reflectance spectra; and (d) outputting the deter-
mined value of oxygen saturation.
37 Claims, 6 Drawing Sheets
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MEASURING TISSUE OXYGENATION
	
	
and scattering by components of the tissue. One form of a
light attenuation equation is based on a series expansion (e.g.,
CROSS-REFERENCE TO RELATED	 a Taylor series expansion) of a measured light attenuation
APPLICATIONS
	
	
spectrum and Beer's law, and includes light attenuation terms
5 that correspond to: absorption by oxygenated heme (hemo-
This application claims priority to U.S. Provisional Appli-	 globin and myoglobin), non-oxygenated heme, water, and
cation Ser. No. 60/809,238 entitled "Measuring Tissue Oxy- 	 other chromophores present in the tissue; scattering in the
gen Saturation," filed on May 30, 2006, the entire contents of 	 tissue; and a constant factor that arises from experimental
which are incorporated herein by reference.
	
	 conditions. These contributions can be quantitatively deter-
io mined by a two-stage numerical fitting procedure, which
STATEMENT AS TO FEDERALLY SPONSORED 	 yields concentrations of oxygenated and non-oxygenated
RESEARCH
	
heme in the tissue. Tissue oxygen saturation can then be
determined from the concentrations of oxygenated and non-
This invention was made with Government support under	 oxygenated heme. Other quantities can also be determined
U.S. Army Medical Research Command Grant Number 15 from measurements of SO z . For example, oxygen tension
W81XWH-06-1-0545, and National Space Biomedical 	 (P02) can be determined from a mathematical equation that
Research Institute Grant Number SMS00205, which is 	 relates POz to SOz.
funded under NASA Cooperative Agreement Number NCC 	 Tissue oxygen saturation and/or oxygen tension can func-
9-58. The Government has certain rights in this invention. 	 tion as important physiological diagnostic and/or predictive
20 indicators. In particular, SO2 is a sensitive probe of capillary
TECHNICAL FIELD	 vasoconstriction, and can be used to track progression and/or
treatment of conditions that result in a variation in blood
This invention relates to measuring properties such as oxy- 	 volume in the tissue, or vasoconstriction/vasodilation in
gen saturation in tissues. 	 response to an insult. Examples of such conditions are hem-
25 orrhage, sepsis, heart disease, and diabetes.
BACKGROUND
	
In general, in one aspect, the invention features a method
for calculating oxygen saturation in a target tissue, where the
Tissue oxygen saturation (SO 2) provides a measure of oxy-	 method includes: (a) directing incident radiation to a target
gen content in red blood cells. Measurement of SOz in tissue	 tissue and determining reflectance spectra of the target tissue
can be used to assess micro-vascular circulation and oxygen 3o by measuring intensities of reflected radiation from the target
supply to tissue cells arising from certain pathologic condi-	 tissue at a plurality of radiation wavelengths; (b) correcting
tions such as sepsis and diabetes, for example, which result in 	 the measured intensities of the reflectance spectra to reduce
impaired vascular blood flow. Tissue SO 2 measurements can	 contributions thereto from skin and fat layers through which
also be used in exercise physiology, where a mismatch	 the incident radiation propagates; (c) determining oxygen
between oxygen demand and supply during periods of exer-
 35 saturation in the target tissue based on the corrected reflec-
cise can be used to determine an extent of physical condition- 	 tance spectra; and (d) outputting the determined value of
ing of a subject.	 oxygen saturation.
Infrared reflectance measurements can be used for non-	 Embodiments of the method can include one or more of the
invasive, quantitative detection of various chemical species in 	 following features. Determining oxygen saturation can
tissue. For example, interrogation of oxygenated and non- 40 include determining light attenuation spectra from the cor-
oxygenated hemoglobin in tissue can be made via reflectance	 rected reflectance spectra, and calculating oxygen saturation
measurements of the tissue at wavelengths that fall within a 	 based on concentrations of oxygenated and deoxygenated
range of about 700-1000 mu. In this wavelength range, many 	 heme in the target tissue that are derived from the light attenu-
chemical species that may be present in the tissue and which 	 ation spectra, where heme includes hemoglobin and myoglo-
are not of interest interact only weakly with incident radia-  45 bin in the target tissue. The concentrations of oxygenated and
tion, and signals arising from hemoglobin can be isolated
	
deoxygenated heme can be derived from the light attenuation
from signals that arise from other chemical components. 	 spectra by fitting the light attenuation spectra to a model light
Infrared radiation typically penetrates relatively deeply into 	 attenuation equation. The light attenuation equation can
tissues, and can be used to probe underneath surface tissues 	 include a Beer's Law equation that includes terms that corre-
such as skin and fat to measure analytes of interest in deeper 50 spond to incident light absorption by oxygenated heme,
muscle and other internal tissues. Suitable systems for per-	 deoxygenated heme, and water in the target tissue. For
forming infrared reflectance measurements in tissue are 	 example, the light attenuation equation can include a series
described, for example, in U.S. Publication Number US 	 expansion (e.g., a Taylor series expansion) of light attenua-
2007/0038041 entitled "SYSTEMS AND METHODS FOR	 tion in a plurality of terms that correspond to Beer's Law
CORRECTING OPTICAL REFLECTANCE MEASURE-  55 absorption terms. The fitting can be performed automatically
MENTS," filed on Apr. 25, 2006, the entire contents of which 	 by a processor.
are incorporated herein by reference.	 The light attenuation equation can include a term that var-
ies linearly with a wavelength of the incident light, the term
SUMMARY	 having a functional form a^. where a is a constant and k is the
60 wavelength of the incident light. The value of a can be con-
Disclosed herein are systems and methods for determining 	 strained during fitting so that a assumes only values that are
tissue oxygen saturation (SO 2) and other quantities such as	 less than or equal to zero. The light attenuation equation can
oxygen tension from infrared spectroscopic measurements. 	 include a constant term independent of the wavelength of the
The systems and methods are based, at least in part, on an	 incident light.
approach to calculating oxygen saturation in tissue based on 65 	 Fitting the light attenuation spectra to a model can include
an equation for light attenuation by the tissue, where the 	 performing a two-stage fitting procedure where, in a first
equation includes terms that correspond to light absorption 	 stage, initial values of one or more model parameters are
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determined, and in a second stage, the light attenuation spec-
tra are fitted to the model, where the model includes the initial
parameter values determined in the first stage. The light
attenuation spectra can be fitted to the model by minimizing
a sum of squared differences between the light attenuation
spectra and light attenuation values determined from the
model.
The light attenuation equation can include a baseline func-
tion derived from a difference between light attenuation val-
ues determined from the light attenuation equation and the
light attenuation spectra. The light attenuation equation can
include a differential path length factor that varies directly
with a scattering coefficient of the target tissue and inversely
with an absorption coefficient of the target tissue. The light
attenuation equation can include a diffuse reflectance equa-
tion derived from a radiation diffusion model of incident light
in the target tissue.
Measuring intensities of reflected radiation can include: (a)
measuring, along a first optical path from a light source to a
detector, reflected radiation from the target tissue that corre-
sponds to a first source -detector spacing; and (b) measuring,
along a second optical path from the light source to the detec-
tor, reflected radiation from the target tissue that corresponds
to a second source-detector spacing different from the first
source-detector spacing. The reflected radiation measured at
the first source -detector spacing can include a first weighting
of contributions from the target tissue and from tissue layers
disposed between the light source and the target tissue, and
the reflected radiation measured at the second source -detector
spacing can include a second weighting of contributions from
the target tissue and from the tissue layers disposed between
the light source and the target tissue different from the first
weighting. The tissue layers disposed between the light
source and the target tissue can be skin and fat layers. Cor-
recting the measured intensities of the reflectance spectra can
include reducing contributions from the skin and fat layers to
the reflected radiation measured at the second source -detector
spacing based on the reflected radiation measured at the first
source-detector spacing.
The method can include determining oxygen tension in the
target tissue based on oxygen saturation in the target tissue.
The method can include assessing a level of vasoconstriction
in a patient based on a measurement of total hemoglobin in a
target tissue of the patient, where total hemoglobin is deter-
mined based on the concentrations of oxygenated and deoxy-
genated heme in the target tissue.
The target tissue can be within a human. The target tissue
can be within an animal. The target tissue can be a muscle
tissue.
The plurality of wavelengths can include at least 100 wave-
lengths or more. The plurality of wavelengths can include
wavelengths from 700 nm to 1000 mu (e.g., wavelengths
from 725 nm to 880 nm).
Embodiments of the method can also include any of the
other method steps disclosed herein, as appropriate.
In another aspect, the invention features a method of moni-
toring blood volume in a patient, where the method includes:
(a) directing incident radiation to a target tissue of the patient
and determining reflectance spectra of the target tissue by
measuring intensities of reflected radiation from the target
tissue at a plurality of wavelengths; (b) correcting the mea-
sured intensities of the reflectance spectra to reduce contri-
butions thereto from skin and fat layers through which the
incident radiation propagates; (c) determining total heme
concentration in the target tissue based on the corrected
reflectance spectra; (d) assessing a blood volume in the
4
patient based on the total heme concentration; and (e) output-
ting the assessed blood volume.
Embodiments of the method can include the following
features.
5 The method can include assessing a stage of progress of at
least one of hemorrhage, sepsis, heart disease, and diabetes in
the patient based on the assessed blood volume. Embodi-
ments of the method can also include any of the other method
steps disclosed herein, as appropriate.
10 In a further aspect, the invention features a method for
calculating oxygen saturation in a target tissue, where the
method includes: (a) directing incident radiation to a target
tissue and determining reflectance spectra of the target tissue
by measuring intensities of reflected radiation from the target
15 tissue at a plurality of radiation wavelengths; (b) determining
light attenuation spectra of the target tissue from the reflec-
tance spectra, and fitting the light attenuation spectra to a
model light attenuation equation; and (c) determining oxygen
saturation in the target tissue based on the fitting of the light
20 attenuation spectra. Fitting the light attenuation spectra to a
model can include performing a two-stage fitting procedure
where, in a first stage, initial values of one or more model
parameters are determined, and in a second stage, the light
attenuation spectra are fitted to the model, where the model
25 includes the initial parameter values determined in the first
stage.
Embodiments of the method can include the following
features.
The model can include a term having a functional form a^.,
so and where the value of a is constrained during the fitting to be
less than or equal to zero. Embodiments of the method can
also include any of the other method steps disclosed herein, as
appropriate.
In another aspect, the invention features a system that
35 includes a light source configured to direct incident radiation
to a target tissue, a detector, and a processor coupled to the
detector and configured to: (a) determine reflectance spectra
of the target tissue; (b) correct the reflectance spectra to
reduce contributions thereto from skin and fat layers through
40 which the incident radiation propagates; and (c) determine
oxygen saturation in the target tissue based on the corrected
reflectance spectra.
Embodiments of the system can include one or more of the
following features.
45 The processor can be configured to determine reflectance
spectra of the target tissue by directing the detector to mea-
sure intensities of reflected radiation from the target tissue at
a plurality of radiation wavelengths. The processor can be
configured to determine oxygen saturation by calculating
50 light attenuation spectra from the corrected reflectance spec-
tra, and calculating oxygen saturation based on concentra-
tions of oxygenated and deoxygenated heme in the target
tissue that are derived from the light attenuation spectra,
where heme includes hemoglobin and myoglobin in the target
55 tissue.
The system can also include: (a) a first radiation path
between the light source and the detector, and corresponding
to a first distance between the light source and the detector;
and (b) a second radiation path between the light source and
60 the detector, and corresponding to a second distance between
the light source and the detector different from the first dis-
tance. Incident radiation from the light source can be directed
along each of the first and second radiation paths to the target
tissue, and reflected radiation from the target tissue can be
65 directed along each of the first and second radiation paths to
the detector. The processor can be configured to reduce con-
tributions to the measured reflectance spectra from skin and
US 7,532,919 B2
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fat layers by measuring reflectance spectra along each of the
first and second light paths, and combining the reflectance
spectra to produce corrected reflectance spectra. Each of the
first and second radiation paths can include an optical fiber.
The processor can be configured to derive the concentra-
tions of oxygenated and deoxygenated heme in the target
tissue by fitting the light attenuation spectra to a model light
attenuation equation. The model light attenuation equation
can include a Beer's Law equation that includes terms that
correspond to absorption of incident radiation by oxygenated
heme, deoxygenated heme, and water in the target tissue.
The processor can be configured to determine oxygen ten-
sion in the target tissue from oxygen saturation. The processor
can be configured to determine total heme concentration in
the target tissue from the concentrations of oxygenated and
deoxygenated heme in the target tissue. The processor can be
configured to assess a blood volume in the target tissue based
on the total heme concentration.
The processor can also be configured to perform any of the
other method steps disclosed herein, as appropriate.
Embodiments can include one or more of the following
advantages.
Oxygen saturation and/or oxygen tension are determined
based on light attenuation measurements performed in the
infrared region of the electromagnetic spectrum. The effects
of absorption and scattering due to analytes other than heme
are smaller in this region than in other spectral regions. As a
result, heme absorption can be quantitatively isolated from
absorption and scattering processes due to other tissue com-
ponents.
Further, the infrared radiation can penetrate relatively
deeply into a patient, interrogating tissue (e.g., muscle tissue)
that is located underneath layers of skin and fat. The penetra-
tion depth of the infrared radiation permits measurement of
oxygen saturation in muscle tissues, for example, which are
typically located relatively deeply underneath layers of skin
and fat. The infrared spectral data can be corrected for light
absorption by skin pigments and light scattering by fat,
thereby permitting even more accurate quantitative determi-
nation of heme absorption than would otherwise be possible
without such corrections. The effects of water absorption in a
patient's tissue can also be quantitatively determined and
separated from heme absorption.
Measurements are performed across a relatively large
number of wavelength channels such as 100 wavelength
channels or more (e.g., 150 wavelength channels ormore, 200
wavelength channels or more, 400 wavelength channels or
more, 600 wavelength channels or more, 1000 wavelength
channels or more). The relatively large number of measure-
ments improves the signal-to-noise ratio of the measured data
relative to instruments that record data from, for example,
between two and six wavelength channels.
The measurements disclosed herein are performed non-
invasively using a low cost, portable measurement system.
Results can be displayed in real-time or near real-time, which
enables continuous monitoring of oxygen saturation and/or
oxygen tension. Where these parameters are correlated with a
particular medical condition in a patient, the progress of the
condition can be evaluated in real-time. The instruments can
operate with manual intervention, or in fully automatic mode
without operator intervention.
Fitting parameters can be constrained appropriately to
enable more accurate quantitative separation of scattering and
absorption processes. For example, coefficients of certain
wavelength-dependent scattering terms can be constrained to
take only non-positive values during fitting of the attenuation
equation to measured light attenuation data, to correlate with
6
typical variations in tissue scattering as a function of light
wavelength. Appropriate choices of fitting constraints can
enable improved quantitative separation of the effects of in
vivo tissue scattering and absorption by oxygenated heme.
5 The light attenuation equation can be fitted to measured
data in a two-stage fitting procedure. A first stage of the fitting
procedure determines initial values of certain fitting param-
eters, and a second stage of the fitting procedure determines a
lowest-error fit of the measured data to the attenuation equa-
10 tion, starting from the initial values determined in the first
stage. The two-stage fitting procedure enables fitting of mea-
sured spectral data without intervention by an operator, and
reduces the overall time required to perform the fitting pro-
cedure. In certain embodiments, the two-stage fitting proce-
15 dure can also improve the accuracy of the fitting results rela-
tive to one-step fitting algorithms.
Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
20 belongs. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or
testing of the present invention, suitable methods and mate-
rials are described below. All publications, patent applica-
tions, patents, and other references mentioned herein are
25 incorporated by reference in their entirety. In case of conflict,
the present specification, including definitions, will control.
In addition, the materials, methods, and examples are illus-
trative only and not intended to be limiting.
The details of one or more embodiments of the invention
30 are set forth in the accompanying drawings and the descrip-
tion below. Other features and advantages of the invention
will be apparent from the description, drawings, and claims.
DESCRIPTION OF DRAWINGS
35
FIG.1 is a schematic diagram of one possible embodiment
of a spectrometer system for measuring oxygen saturation in
a target tissue.
FIG. 2 is a schematic diagram of another embodiment of a
40 spectrometer system for measuring oxygen saturation in a
target tissue.
FIG. 3 is a flow chart showing an exemplary series of steps
for determining oxygen saturation in a target tissue from light
attenuation spectra for the target tissue.
45 FIG. 4 is a plot showing measured percent change in total
hemoglobin as a function of measured percent change in
stroke volume for a patient undergoing a lower body negative
pressure test protocol.
FIG. 5 is a plot showing measured percent change in total
So hemoglobin as a function of measured percent change in total
peripheral resistance for a patient undergoing a lower body
negative pressure test protocol.
FIG. 6 is a plot showing theoretical light attenuation spec-
55 tra calculated for a non-scattering target tissue at a series ofdifferent tissue oxygen saturation values.
FIG. 7 is a plot showing theoretical light attenuation spec-
tra calculated for a scattering target tissue at a series of dif-
ferent tissue oxygen saturation values.
60	 FIG. 8 is a plot comparing actual and estimated values of
oxygen saturation in different target tissues.
FIG. 9 is a plot comparing oxygen saturation values mea-
sured from withdrawn blood samples and from non-invasive
infrared reflectance measurements for patients at various
65 stages of a lower body negative pressure test protocol.
FIG. 10 is a plot comparing oxygen tension values mea-
sured from withdrawn blood samples and from non-invasive
US 7,532,919 B2
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infrared reflectance measurements for patients at various
stages of a lower body negative pressure test protocol.
Like reference symbols in the various drawings indicate
like elements.
DETAILED DESCRIPTION
Disclosed herein are methods and systems for obtaining
measurements of tissue oxygen saturation and other physi-
ological quantities such as oxygen tension from infrared
reflectance spectra of a target tissue (e.g., a tissue in a human
or an animal). Values of these quantities are derived by ana-
lyzing a light attenuation model that accounts for tissue
absorption and scattering. Reflectance spectra of a target tis-
sue are first measured by a suitably configured spectrometer
system, and then the spectra are analyzed, for example, by a
processor coupled to the spectrometer system.
Measurement Systems
A variety of measurement systems can be used to measure
attenuation by a target tissue of incident light in the infrared
region of the electromagnetic spectrum. FIG.1 shows a sche-
matic diagram of one embodiment of such a measurement
system. Measurement system 10 includes a light source 12, a
probe head 14, a detector 16, a processor 18, and a display 19.
Light source 12 provides radiation which is coupled into light
path 20 and propagates along light path 20 from light source
12 to probe head 14. The radiation emerges from light path 20
and is incident on a surface 32 of a target tissue 30 adjacent to
probe head 14. A portion of the incident radiation is reflected
by target tissue 30 and enters light path 22. The reflected
radiation propagates along light path 22 to detector 16. Detec-
tor 16 is configured to measure an intensity of the reflected
radiation, as a function of wavelength. Processor 18, e.g., a
stand-alone processor or a portion of an external computer
system, coupled to detector 16 via communication line 24,
provides configuration signals to detector 16. In addition,
processor 18 is configured to receive, via communication line
25, the spectral reflectance intensity data recordedby detector
16. Processor 18 can be configured to transform the spectral
reflectance data into light attenuation data, for example, that
measures wavelength-dependent attenuation of the incident
radiation by target tissue 30. As shown in FIG.1, processor 18
is in electrical communication with display 19. Spectral
reflectance data, wavelength-dependent light attenuation
data, and/or other data or physiological quantities determined
from the measured data, can be output from processor 18 to
display 19. Alternatively, or in addition, measured and/or
calculated data can be output from processor 18 to another
processor (not shown) for further processing, to a storage
medium, or to another device (e.g., a computer and/or a
wireless communications device).
The ends of light paths 20 and 22 are separated by a dis-
tance d in probe head 14. In some embodiments, the distance
d can be relatively short, such as about 5 mm or less (e.g.,
about 4 mm or less, about 3 mm or less, about 2 mm or less,
or about 1 mm or less). In other embodiments, the distance d
can be relatively long, such as about 20 mm or more (e.g.,
about 25 mm or more, about 30 mm or more, about 35 mm or
more). In certain embodiments, probe head 14 is configured
to permit adjustment of the distance d by a system operator.
For example, the distance d canbe adjusted to acquire spectral
data that includes contributions from tissues within a certain
depth t of surface 32 of target tissue 30 adjacent to probe head
14. In general, the larger the distance d, the greater the depth
of tissue t contributing to the measured light attenuation data.
Light source 12 can, in general, include a wide variety of
sources. For example, light source 12 can include an incan-
8
descent source, one or more light-emitting diodes, a laser-
based source, or other types of sources. Light source 12 can
provide radiation in one or more selected regions of the elec-
tromagnetic spectrum, such as the ultraviolet region, the vis-
5 ible region, the infrared region, or other regions. In some
embodiments, for example, light source 12 is configured to
provide radiation in the infrared region of the electromagnetic
spectrum. The radiation can include wavelengths from about
700 mu to about 1000 mu, for example.
10 In certain embodiments, the radiation provided by light
source 12 can include multiple wavelengths. For example, a
full-width at half maximum of the distribution of wavelengths
of the radiation can be about 10 mu or more (e.g., about 20 mu
or more, about 50 nm or more, about 100 mu or more, about
15 150 nm or more, about 200 nm or more, about 250 nm or
more). The distribution of wavelengths of the radiation can be
produced from a single source element such as an incandes-
cent element or a broadband light emitting diode, for
example, or from multiple source elements (e.g., multiple
20 light emitting diodes) operating simultaneously or sequen-
tially.
Light paths 20 and 22 can be formed from materials suit-
able for directing the radiation provided by light source 12. In
certain embodiments, for example, one or both of light paths
25 20 and 22 can be waveguides formed by one or more optical
fibers. In some embodiments, one orboth of light paths 20 and
22 can be open passageways formed in probe head 14 and
sized to permit the radiation to pass through. In certain
embodiments, for example, either or both of light source 12
so and detector 16 can be placed in direct contact with the skin of
patient, or in direct contact with a target tissue (e.g., without
overlying skin and/or fat layers), so that light paths 20 and/or
22 do not include open passageways, but instead include the
optical trajectories along which incident and reflected radia-
35 tion propagate in the target tissue. In some embodiments, one
or both of light paths 20 and 22 can include other types of
waveguides such as photonic crystal fibers and/or light trans-
mitting polymer materials.
Detector 16 is configured to measure a wavelength-depen-
4o dent intensity of reflected radiation from target tissue 30.
Typically, detector 16 is a spectral detector such as a spec-
trometer, with a wavelength-dispersing element such as a
diffraction grating that is configured for use in a wavelength
region that includes the wavelengths in the radiation provided
45 by light source 12. Suitable spectrometers are available, for
example, from Ocean Optics Inc. (Dunedin, Fla.). Detector
16 can measure intensities of radiation at multiple wave-
lengths. For example, in some embodiments, detector 16 is
configured to measure the intensity of optical radiation at
5o about 50 or more distinct wavelengths (e.g., about 100 or
more distinct wavelengths, about 150 or more distinct wave-
lengths, about 200 or more distinct wavelengths, about 400 or
more distinct wavelengths, about 600 or more distinct wave-
lengths, about 1000 or more distinct wavelengths).
55 The spectral intensity data measured by detector 16, which
is typically wavelength-dependent reflectance data from tar-
get tissue 30, can be converted to wavelength-dependent light
attenuation data (e.g., a light attenuation spectrum of target
tissue 30) by processor 18 using well known methods. In the
60 subsequent discussion, reference is made to light attenuation
spectra of target tissue 30, but the methods and systems dis-
closed herein can also be used to process spectral reflectance
data directly, since the light attenuation and spectral reflec-
tance data are related by a simple mathematical transforma-
65 tion (see, e.g., Equation (2) discussed in the next section).
In addition to converting spectral reflectance data to light
attenuation data, processor 18 can be configured to analyze
US 7,532,919 B2
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the light attenuation data to obtain measurements of physi-
ologically important quantities such as oxygen saturation and
oxygen tension, as will be discussed in further detail below. In
general, processor 18 can be configured to perform any of the
analysis steps that are discussed herein.
In some embodiments, optical reflectance spectra can be
measured at more than one source-detector spacing d. For
example, FIG. 2 is a schematic diagram of an embodiment of
a measurement system 50 that includes two different source-
detector spacings, each of which can be fixed, or adjusted by
an operator. Many of the components of measurement system
50 are similar to the components of measurement system 10
and will not be discussed further. Measurement system 50
includes a first detection light path 22a spaced from light path
20 in probe head 14 by a distance d a, and a second detection
light path 22b spaced from light path 20 in probe head 14 by
a distance db greater than da.
Spectral reflectance measurements can be recorded by
detector 16 at multiple source-detector distances to reduce
and/or remove the spectral absorption and/or scattering
effects of overlying tissue layers from the spectra of under-
lying tissues of interest. For example, reflectance spectra
recorded at the short source-detector distance da typically
include a first weighting of contributions from tissues near
surface 32 and from the deeper interior of target tissue 30
(e.g., primarily from tissues near surface 32 of target tissue
30). Reflectance spectra recorded at the longer source-detec-
tor distance db typically include a second weighting, different
from the first weighting, of contributions from tissues near
surface 32 and from the deeper interior of target tissue 30
(e.g., spectra at the longer source-detector distance typically
include significant contributions from both tissues near sur-
face 32, and from tissues underlying surface 32). Reflectance
data recorded at two different source-detector distances can
be processed using suitable algorithms to remove spectral
contributions due to overlying tissue layers adjacent to sur-
face 32, retaining primarily spectral contributions due only to
the underlying (e.g., deeper) tissue layers. In addition, in
some embodiments, the source-detector distances can be
adjusted by an operator to improve the selectivity of the
spectral reflectance measurements (e.g., to selectively inter-
rogate tissues at particular depths below the surface of a
patient's skin).
An as example, in some embodiments, target tissue 30 can
include layers of skin and fat proximal to probe head 14, and
a muscle tissue of interest that underlies the skin and fat layers
(e.g., at a larger distance from probe head 14). Contributions
to the light attenuation data that arise from light absorption
and/or scattering by the skin (including skin pigments) and fat
layers can be reduced or removed from the light attenuation
data to improve the accuracy with which the muscle tissue of
interest is selectively interrogated. Suitable measurement
systems and processing algorithms are disclosed, for
example, in U.S. Publication Number US 2007/0038041
entitled "SYSTEMS AND METHODS FOR CORRECTING
OPTICAL REFLECTANCE MEASUREMENTS"
In some embodiments, spectral reflectance data at multiple
source-detector distances can be measured by systems having
a single detection light path and multiple source light paths
(e.g., multiple paths for coupling light from one or more
radiation sources to probe head 14). In general, the particular
configuration of the measurement system does not substan-
tially change the processing algorithms used to remove the
spectral effects of overlying tissue layers, nor does it change
the analysis algorithms that are used to determine quantities
such as oxygen saturation and oxygen tension from the light
attenuation spectra.
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Having measured spectral reflectance data from target tis-
sue 30 and transformed the data into wavelength-dependent
light attenuation data corresponding to the target tissue, pro-
cessor 18 is configured to analyze the light attenuation data to
5 obtain values of quantities of interest for the target tissue.
Various analysis algorithms implemented in processor 18 for
obtaining these quantities are disclosed below.
Determination of Oxygen Saturation
10 In tissue oximetry, infrared radiation can be used to mea-
sure the heme component in blood. Although radiation in the
visible portion of the electromagnetic spectrum is also
absorbed by blood heme, infrared light typically penetrates
deeper into tissue, and the effects of light scattering are typi-
15 cally smaller at infrared wavelengths than at visible wave-
lengths. In muscle cells, for example, myoglobin and hemo-
globin are each present in the incident radiation pathway, and
each absorbs infrared radiation. In small vessels (e.g., arteri-
oles, capillaries, and venules), changes in infrared absorption
20 primarily reflect changes in concentrations of oxygenated and
non-oxygenated heme. As a result, tissue oxygen saturation
(S02) is defined according to the equation
25	 S02 _	 c(Hb02+Mbo2)
	
(1)
c(Hb02+MbO2) + c(Hb+Mb)
where c(,Ub02+Mbo2) is the total concentration of oxygenated
30 heme in the tissue (Hb=hemoglobin, Mb myoglobin) and
c(ab+Mb) is the total concentration of deoxygenated heme in
the tissue. The sum c,,b+Mb+cffb02+Mbo2 is the total concen-
tration of heme in the tissue. Hemoglobin and myoglobin
have similar absorption profiles through much of the infrared
35 region of the spectrum, and the infrared reflectance measure-
ment techniques disclosed herein are sensitive to both hemo-
globin and myoglobin.
A model light attenuation spectrum (AmodeZ(^ )) for a target
tissue exposed to incident light is defined in general as the
40 logarithm of the ratio of the incident light intensity and the
reflected light intensity. A variety of different models can be
used to describe the light attenuation spectrum of a target
tissue. In some embodiments, for example, a Taylor series
expansion method can be used to express the light attenuation
45 spectrum as a function of one or more absorption terms, as
described in Stratonnikov, A. A. and Loschenov, V. B.,
"Evaluation of blood oxygen saturation in vivo from diffuse
reflectance spectra," Journal ofBiomedical Optics 6: 457-467
(2001). A suitable Taylor series expansion for Amo,,Z(X) is
50
Amoeea ( ;L) =In( to ('L))	
(2)
t(;L)
_ (co + c ) A) + In(10) - (L)
55
IcHb+Mb£Hb ( ;L) + CHb02+MbO2 £HbO2( ;L) + cwat --1(x)1
where I O (X) is an incident light intensity (e.g., the light source
60 intensity), I(X) is a reflected light intensity from the tissue, X
is a light wavelength, c o and c l are constants, <L> is a mean
path length of the reflected light through the tissue, e, b(X) is
a wavelength-dependent extinction coefficient for deoxygen-
ated hemoglobin, Eab02(X) is a wavelength-dependent
65 extinction coefficient for oxygenated hemoglobin, c_,, is a
concentration of water in the tissue, and E_,,(X) is a wave-
length-dependent extinction coefficient for water. Hemoglo-
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11
bin and myoglobin have similar extinction coefficients in the
infrared region of the spectrum, and so the extinction coeffi-
cients of oxygenated and deoxygenated hemoglobin are also
used to model myoglobin absorption in Equation (2). The
determination of values for the various parameters in Equa- 5
tion (2) is discussed in further detail below.
Typically, it can be difficult to determine the absolute light
source intensity I o(X) under experimental conditions.
Accordingly, in some embodiments, reflected light intensity
from a 99% reflectance standard, I t(^), is used in place of 10
Io(X) when modeling light attenuation. Suitable 99% reflec-
tance standards include, for example, Model SRT-99-050,
available from Labsphere, Inc. (North Sutton, N.H.). With the
experimental reference light intensity 1,,,(X) measured
instead of IJX), the measured light attenuation spectrum, 15
A,,P (X), is
	
n^( 
I.f (A)	 3)
	
A p(t) 1 l I ( ;L)	 20
12
spond to one or more of oxygenated hemoglobin and myo-
globin, deoxygenated hemoglobin and myoglobin, water, and
other species present in the target tissue. A suitable model that
can be selected is given by Equation (2), for example. In
general, the systems disclosed herein can include one or more
models for describing light attenuation in the target tissue. In
some embodiments, the systems include only a single model.
In certain embodiments, the systems include multiple mod-
els, and selection of a model A_,,,,(X) can be based on input
from a human operator, for example.
In step 106, the model selected in step 104 is used to
determine calculated values of light attenuation in the target
tissue, and various model parameters are adjusted to mini-
mize a sum of squared differences between the calculated
values of light attenuation and the measured light attenuation
spectra. The sum of squared differences between the calcu-
lated values of light attenuation and the measured light
attenuation spectra, x 2, can be written as
The reference light intensity 1,,,(X) typically differs from
IJX) by a wavelength-independent constant factor, which
appears as a constant additive contribution to the experimen-
tally-measured light attenuation spectrum of a target tissue.
The constant co in Equation (2) accounts for this additive
contribution to the light attenuation spectrum. In addition, co
also accounts for wavelength-independent absorption and/or
scattering by chromophores and other species in the target
tissue other than hemoglobin, myoglobin, and water. Simi-
larly, the constant c, accounts for wavelength-dependent light
absorption and/or scattering from chromophores and other
species in the target tissue other than hemoglobin, myoglo-
bin, and water. Terms on the right-hand side of Equation (2)
which are multiplied by <L> account for attenuation of inci-
dent light by hemoglobin, myoglobin, and water in the target
tissue.
Typically, light attenuation in the target tissue can arise
from both light absorption and light scattering processes. For
example, light is absorbed by hemoglobin in small blood
vessels and myoglobin in cells, by both intravascular and
extravascular water, and by melanin pigments in skin. Light
can be scattered by physical structures such as blood vessels
and muscle fibers, and also by fat which overlies muscle
tissue of interest (e.g., fat that is disposed between a probe
head of a measurement system and the muscle tissue).
The systems and methods disclosed herein can generally
be applied to the calculation of oxygen saturation and other
physiological quantities in many different types of tissue,
including muscle tissue and non-muscle tissue, and any of the
steps discussed in connection with the determination of SO2
can also be performed to calculate SO 2 in both muscle tissue
and non-muscle tissue. Measuring oxygen saturation in
muscle tissue provides a particularly sensitive diagnostic
indicator of vasoconstriction/vasodilation, for example.
FIG. 3 is a flow chart 100 that shows a series of steps for
calculating oxygen saturation in a target tissue from light
attenuation spectra, A,,P (X), for the target tissue. Ina first step
102, one or more light reflectance spectra are collected from
a target tissue, and light attenuation spectra are calculated via
Equation (3).
In optional step 104, a model Amo,,Z(X) can be selected to
describe light attenuation in the target tissue. In some
embodiments, for example, the model selected accounts for
both light absorption and light scattering in the target tissue.
In certain embodiments, the model includes terms that corre-
x —x,a	 (4)
[A—dea(k) — A—p(;L;)1'
25
where the light attenuation spectra are measured (and theo-
retical light attenuation values calculated) at a series of wave-
lengths X, between X_,, and Xm,,. The value of x2 is mini-
30 mized to yield values of certain adjustable parameters in
Amodei(^). For example, if the model given by Equation (2) is
selected, the function x2 is minimized to yield values of
parameters co ,
 
cv cab+Mb, cab02+Mb021 cwat, and <L>.
To obtain accurate values of the model parameters, a non-
35 linear least squares fitting algorithm is used to minimize x2 in
Equation (4). In some embodiments, fitting constraints on
certain model parameters can also be used to improve the
accuracy of the parameter values that are obtained. For
example, shorter wavelength light typically scatters more
40 efficiently from tissue structures than longer wavelength
light, and a wavelength-dependent scattering efficiency curve
can therefore be described by a linear functional form with a
non-positive slope. A reduced scattering coefficient for the
tissue structures, µ ', can generally be described by a function
45 such as
µ,'—a+bT	 (5)
where a and  are constants, with b-_0. Typically, the portions
50 of the measured light attenuation spectra that are due to oxy-
genated hemoglobin have a positive slope in the infrared
region of the spectrum. Thus, when the model given by Equa-
tion (2) is selected, parameter c l can be constrained during
fitting so that c  -_0. This constraint enables improvedparam-
55 eter value determination by eliminating cross-talk between
contributions to the light attenuation spectra from oxygenated
heme, scattering, and a relatively smooth background.
For certain tissues, it may be possible to make good initial
estimates for the values of parameters cab+Mb, cab02+Mb021
6o and cwat (e.g., in healthy human patients). For other tissues, it
may be more difficult to arrive at good initial estimates for
these parameters. Making initial estimates of parameter val-
ues typically involves operator intervention, however, and is
subject to variability that arises due to differences in skill
65 levels of human operators. Typically, for example, in healthy
human patients, the value of cab+Mb can be about 40 µcool/L,
the value of cab02+Mb02 can be about 60 µmol/L, and the
US 7,532,919 B2
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value of cwat can be about 60%. These values can be used as
initial estimates for the parameters cab+Mb, c11b02+Mb02, and
C-at*
As an alternative to relying on input from a human opera-
tor, the systems and methods disclosed herein can also deter-
mine both initial values and final values of model parameters
in automated fashion (e.g., without operator input) using a
two-stage fitting procedure. The two-stage fitting procedure
can, in general, be applied to any of the models disclosed
herein to automatically determine good initial values of some
or all of the model parameters, and then to determine final
parameter values by minimizing the value of x2 in Equation
(4).
As an example, when the model given by Equation (2) is
selected in step 104, good initial values of c o, c l , and <L> can
be determined using a sweep method by fixing the values of
the parameters cab+Mb, Cab02+MbO2, and cwat, and using a
least-squares minimization procedure to vary the values of
parameters co, c l , and <L>. This technique corresponds to
minimizing the value of x2 in Equation (4) with only c o, cl,
and <L> as adjustable parameters. When good initial values
of co, c l , and <L> have been determined via minimization of
Z2, these values are fixed and the value of x2 in Equation (4)
is again minimized via the sweep method by allowing param-
eters cab+Mb, CUb02+MbO2, and cwat to vary. The values for
these parameters obtained from the minimization procedure
correspond to good initial values.
The second stage of the two-stage fitting procedure
includes minimizing the value of x2 in Equation (4) with each
of the six parameters CO , c l , <L>, cab+Mb, Cab02+MbO2, and
cwat allowed to vary (subject to any fitting constraints
imposed, as discussed previously), and starting from the good
initial values of these six parameters determined in the first
stage of the procedure. The values of these parameters
obtained after the second stage of the procedure are the final
values of the parameters. In general, any fitting algorithm that
is capable of minimizing the value of x2 in Equation (4)
subject to any applied constraints can be used in the systems
and methods disclosed herein. One example of a fitting algo-
rithm that can be used to minimize value of x2 in Equation (4)
is the Levenberg-Marquardt algorithm.
The two-stage fitting procedure discussed above can pro-
vide a number of advantages. In particular, by initiating the
second stage of the fitting procedure with good initial values
of the parameters, the second stage proceeds more rapidly to
convergence than it would otherwise. Also, fitting results are
typically more accurate, because the nonlinear least-squares
fitting algorithm is less likely to get stuck in a local (but not
necessarily global) minimum.
One algorithm that can be used to fit light attenuation
spectra to a selected light attenuation model in the disclosed
systems and methods is a type of genetic algorithm called the
Differential Evolution (DE) method, which is described in
Price, K. V., "Differential Evolution: A practical approach to
global optimization," (Germany: Springer-Verlag, 2005). The
DE algorithm is a global optimization algorithm that con-
verges to an extreme value of a function irrespective of its
initial population. The DE algorithm typically converges
faster and uses fewer control variables than other global opti-
mization algorithms. Because the DE algorithm converges to
a global minimum, the DE algorithm can be used, in some
embodiments, without performing the first stage of the fitting
procedure discussed above. That is, a one-stage fitting proce-
dure in which the DE algorithm is used to fit light attenuation
spectra to a light attenuation model without first fitting the
spectra via the sweep method to determine initial estimates of
model parameters can be used.
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When final values of the model parameters have been
determined, oxygen saturation in the target tissue is calcu-
latedin step 108. Oxygen saturation is calculated according to
Equation (1); therefore, the model selected in step 104
5 includes parameters cab+Mb and cab02+Mb O2• Values of these
parameters are determined in step 106, and then S0 2 is cal-
culated from the values of these parameters in step 108.
Determination of Oxygen Tension
10 In step 110, which is optional in flow chart 100, oxygen
tension in the target tissue is calculated from the value of
oxygen saturation determined in step 108. Oxygen tension
can be calculated from oxygen saturation using a variety of
algorithms. For example, oxygen tension can be calculated
15 using the following relationship, which is described in Sev-
eringhaus, J. W., "Simple, accurate equations for human
blood 02 dissociation computations," J. Appl. Physiol.: Res-
pirat. Environ. Exercise Physiol., 46:599-602 (1979):
20
P02 = exp 0.385 . ln(SO2-1 - 1) 1 +3.32- (72'SO2)-i - S6 1	
6)
6
25 Equation (6) permits straightforward calculation of oxygen
tension from oxygen saturation under standard physiological
conditions in step 110 of flow chart 100.
Applications
30 Oxygen saturation and/or oxygen tension, measured via
the systems and methods disclosed herein, provide a sensitive
diagnostic indicator of capillary vasoconstriction in patients.
Early in the process of hemorrhage and internal bleeding,
capillaries in muscle tissues vasoconstrict to direct blood to
35 the heart and brain where it is most needed. Vasoconstriction
also helps to maintain blood pressure at relatively normal
levels; as a result, blood pressure typically provides only a
late-stage indicator of hemorrhagic shock.
To evaluate the sensitivity of the systems and methods
40 disclosed herein, a set of ten test subjects underwent a test
protocol that included progressively increasing magnitudes
of lower body negative pressure (LBNP). The LBNP protocol
consisted of a five minute baseline period, followed by five
minute intervals of chamber decompression to —15, —30, —45,
45 and —60 mm Hg, followed by additional increments of —10
mm Hg every five minutes until either the onset of cardiovas-
cular collapse, or the completion of five minutes at —100 mm
Hg. Infrared reflectance spectra were recorded continuously
throughout the protocol using a fiber optic sensor with both
50 short-distance and long-distance source-detector spacings.
The sensor was placed on the flexor digitorum profundus
muscle of the forearm.
Oxygen saturation and oxygen tension in the muscle tissue
were calculated from light attenuation spectra generated from
55 the reflectance spectra using the methods disclosed above.
The reflectance spectra were corrected to remove contribu-
tions from light absorption and/or scattering by skin pigments
and fat prior to generating the light attenuation spectra. A
blood sample was withdrawn from each test subj ect in the last
60 minute of each stage of the LBNP protocol. Oxygen satura-
tion for each subject was measured from the blood sample
using a co-oximeter instrument, and oxygen tension was mea-
sured using a blood gas analyzer.
In addition, for each subject at each level of the LBNP
65 protocol, changes in stroke volume (SV), total peripheral
resistance (TPR), and total hemoglobin (HbT) the sum of
oxygenated and deoxygenated hemoglobin and myoglobin in
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15
the muscle tissue were determined relative to baseline val-
ues of these parameters. Beat-to-beat stroke volume was mea-
sured non-invasively using thoracic electrical bioimpedance
with an HIC-2000 Bio-Electric Impedance Cardiograph
(available from Bio-Impedance Technology, Chapel Hill,
N.C.). The thoracic electrical bioimpedance technique is
based on the resistance changes in the thorax to a low inten-
sity (e.g., 4 mA), high frequency (e.g., 70 kHz) alternating
current applied to the thorax by two outer-surface electrodes
placed at the xiphoid process at the midaxillary line. Ventricu-
lar SV (in units of mL/beat) was determined from the partly
empirical formula
SV = P. ( o - LVET dt^m^
where  (in units of ohm-cm) is the blood resistivity (typically
about 135 ohm-cm), f (in units of cm) is a mean distance
between two inner pick-up electrodes, Z o (in units of ohms) i s
a mean baseline thoracic impedance, LVET (in units of sec-
onds) is a left ventricular ejection time, and (dZ/dt) m,„ is a
height of a measured thoracic impedance vs. time peak (e.g.,
a Z-point) from a zero line. Cardiac output (Q) was calculated
as the product of heart rate (HR) and SV, and TPR was
estimated by dividing a mean value of arterial pressure by Q.
FIG. 4 shows the measured percent change in total hemo-
globin as a function of the measured percent change in stroke
volume. The relationship between the changes in total hemo-
globin and stroke volume is approximately linear, as indi-
cated by the solid line in FIG. 4. Without wishing to be bound
by theory, one possible explanation for the relationship
shown in FIG. 4 is that stroke volume falls as blood volume
decreases. In FIG. 5, the percent change in total hemoglobin
is plotted as a function of the percent change in total periph-
eral resistance. The relationship is again approximately linear
as shown by the solid line. However, FIG. 5 shows that
changes in total hemoglobin are inversely correlated with
changes in total peripheral resistance. Typically, total periph-
eral resistance increases when vasoconstriction occurs. Thus,
measurement of total hemoglobin in muscle tissue (by deter-
mining concentrations of oxygenated and deoxygenated
hemoglobin, as discussed above) provides an accurate diag-
nostic for the onset and progression of vasoconstriction in
patients.
More generally, vasoconstriction and/or vasodilation pro-
duce changes in blood volume in a target tissue, and by
monitoring total hemoglobin, blood volume in the tissue
(e.g., changes in blood volume over time in a patient) can be
assessed. Values of SO z and POz determined via the methods
disclosed herein also provide sensitive probes of blood vol-
ume in a target tissue, and can be used for monitoring and
assessment purposes. In general, measurements of quantities
such as HbT, SO2 , and P02 are useful for tracking progression
and treatment of any disease or condition that results in varia-
tion of blood volume in tissues, and/or vasoconstriction/va-
sodilation in response to an insult. Examples of conditions for
which progression can be tracked include: diagnosis of, and
evaluation of treatment for, hemorrhage and sepsis; microvas-
cular abnormalities that accompany heart disease and diabe-
tes; and effects of drugs that raise blood pressure through
vasoconstriction and/or vasodilation. In animal patients,
regional effects of drugs on specific organs can be tracked.
As an example, when a patient undergoes hemorrhaging,
the loss of blood volume in certain patient tissues can be
monitored by measuring total hemoglobin. Further, as shown
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in FIGS. 4 and 5, total hemoglobin scales linearly with blood
volume. Therefore, by monitoring HbT over time, a stage of
progress of a hemorrhage can be assessed. Changes in HbT
can be used to assess whether a hemorrhage has been halted or
5 is under control, for example, or whether the hemorrhaging
condition is worsening.
As another example, when a patient suffers from sepsis —a
microcirculatory disease small blood vessels in certain tis-
sues of the patient become clogged, resulting in a smaller
10 blood volume (and oxygen-depleted blood) being present in
the patient's tissues. Generally, as sepsis persists, the level of
oxygen-depletion in blood tissue increases. If perfusion is
restored, the sepsis condition is alleviated, and both blood
oxygenation and blood volume increase in the patient's tis-
15 sues. By monitoring HbT and/or SO2 and/or P02 in patient
tissues, as disclosed herein, the rate of progress of sepsis can
be assessed. For example, when a sepsis condition in a target
tissue is worsening, the value of HbT in the tissue decreases
with decreasing blood volume. As sepsis in the tissue is alle-
20 viated, the value of HbT in the tissue increases with increas-
ing blood volume. Similar correlations apply to assessing
sepsis based on blood volume determined from measure-
ments of SOz and POz in the target tissue.
As a third example, when a patient suffers from heart
25 disease or diabetes, atherosclerosis which results from these
conditions prevents vasoconstriction in response to a chal-
lenge. In contrast, in a healthy patient, vasoconstriction in
response to a challenge occurs to maintain blood pressure.
Thus, progress of a condition such as heart disease or diabetes
30 can be assessed by monitoring HbT and/or SO 2 and/or P02 in
the patient. Typically, for example, a patient suffering from
one of these conditions is either tilted or subjected to an
exercise protocol which represents a challenge, and values of
SOz and/or POz and/or and HbT are determined from a
35 selected target tissue of the patient. Due to the inability of the
patient's blood vessels to vasoconstrict, measured changes in
SOz and/or POz and/or and HbT for the patient will be smaller
than the measured changes in these parameters would be for
a healthier patient. By measuring the difference in the values
40 of SOz and/or POz and/or and HbT for the afflicted patient's
tissue relative to standard values for a healthy patient's tissue
(or relative to values of these parameters measured from the
same patient at an earlier stage of the disease), the progress of
conditions such as heart disease and diabetes can be assessed.
45 In general, as discussed above, measurements of quantities
such as HbT, SO2, and P02 for assessment and tracking of
various conditions are performed during interventions that
stimulate vasoconstriction to maintain blood pressure and/or
vasodilation to improve blood flow. Examples of such inter-
50 ventions include occluding one or more blood vessels, exer-
cising a subject, and tilting a subject.
Implementation
The equations and algorithms disclosed herein can be
55 implemented in hardware or in software, or in a combination
of both. The method steps and figures disclosed herein can be
implemented in computer programs using standard program-
ming techniques. The programs can be designed to execute on
programmable processors (such as processor 18) or comput-
60 ers, e.g., microcomputers, each including at least one proces-
sor, at least one data storage system (including volatile and
non-volatile memory and/or storage elements), at least one
input device, such as a keyboard or push button array, and at
least one output device, such as a CRT, LCD, or printer.
65 Program code is applied to input data to perform the functions
described herein. The output information is applied to one or
more output devices such as a printer, or a CRT or other
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monitor, or a web page on a computer monitor with access to
a website, e.g., for remote monitoring.
Each program used in the systems disclosed herein is pref-
erably implemented in a high level procedural or object ori-
ented programming language to communicate with a com-
puter system. However, the programs can be implemented in
assembly or machine language, if desired. In any case, the
language can be a compiled or interpreted language.
Each such computer program can be stored on a storage
medium or device (e.g., ROM or magnetic diskette) readable
by a general or special purpose programmable computer, for
configuring and operating the computer when the storage
medium or device is read by the computer to perform the
procedures described herein. The programs can also be con-
sidered to be implemented as a computer-readable storage
medium, configured with a computer program, where the
storage medium so configured causes a processor in the com-
puter to operate in a specific and predefined manner to per-
form the functions described herein.
Although any communications network can be used to
obtain results from remote monitoring, the Internet or wire-
less systems provide useful choices to transmit data.
18
Ae,(A) _ -ln 
5	 V2)T sinh(c- (A) - d)
where the quantity a(X) is calculated according to
10	
6(k)= 3µa(^)'Ga(^)+µ^'(^)7	 (10)
To calculate the light attenuation spectra for the three dif-
ferent light scattering target tissues, values for the concentra-
tions of oxygenated and deoxygenated hemoglobin were
15 selected to fix the theoretical values of SO2, and values for the
absorption coefficient µ a(X) were selected. In addition, values
of the reduced light scattering coefficient µ '(X) for each of the
light scattering target tissues were selected. The three differ-
ent light scattering target tissues corresponded to tissues in a
20 forearm, a calf, and an intact head of a patient. The reduced
scattering coefficients µ '(X) for each of these tissues were
calculated according to Equations (11), (12), and (13),
respectively:
25
EXAMPLES	 µ (^) - 5.1 - A + 11	 (11)
1000
The invention is further described in the following	 8.9 -A
	
(12)
examples, which are not intended to limit the scope of the	 µs(^) - 1000 + 16.3
invention described in the claims. 	 30 6.5 l	 13)
µ,(;L)	 1000 +14.5
Example 1
To evaluate the accuracy of the systems and methods dis-
closed herein, simulated tissue attenuation spectra were cal-
culated for four different light scattering conditions in a target
tissue, and the method steps of FIG. 3 were applied to the data
from each of the four light scattering conditions to determine
values of oxygen saturation. The four light scattering condi-
tions correspond to four different target tissues of interest. For
each target tissue, simulated light attenuation spectra were
calculated for each of eight different theoretical SO 2 values:
0%, 10%, 20%, 40%, 50%, 60%, 80%, and 100%.
To generate light attenuation spectra that corresponded to a
non-scattering, absorbing target tissue, a Lambert-Beer equa-
tion with terms that correspond only to contributions from
hemoglobin was used:
A (T) -In (10) 'E'[CHbEHb+CHb02EHb02+Cw Ew ]	 (8)
where L is a path length of the attenuated light through the
target tissue, cab, Cffb02, and cwat are concentrations of
deoxygenated hemoglobin, oxygenated hemoglobin, and
water in the target tissue, respectively, and Eab(X), EF1b02(X)1
and cwat(X) are extinction coefficients of deoxygenated hemo-
globin, oxygenated hemoglobin, and water as a function of
the wavelength X. Values of these parameters were selected to
generate light attenuation spectra for a non-scattering,
absorbing target tissue.
Light attenuation spectra were also calculated for three
different target tissues in which light scattering occurred. A
single layer infinite slab diffusion model was used to generate
light attenuation spectra for selected values of a tissue absorp-
tion coefficient µ,(X), a reduced scattering coefficient
and a source-probe spacing d, from a model with the func-
tional form
Equations (11)-(13) are described in Matcher, S. J. et al.,
35 "In vivo measurements of the wavelength dependence of
tissue-scattering coefficients between 760 and 900 nm mea-
sured with time-resolved spectroscopy," Applied Optics,
36:386-396 (1997). In Equations (11)-(13), µ '(X) is in units
of cm-' and X is in units of mu. Light attenuation spectra for
40 the three different target tissues corresponding to Equations
(11)-(13) were calculated at a series of wavelength points
between 725 nm and 880 mu.
To assess the accuracy of values of SO 2 determined by
fitting the calculated light attenuation data to a light attenua-
45 tion model, a coefficient of determination R 2 between the
measured and theoretical values of SO 2 for each tissue was
calculated. In addition, values of the root-mean-square error
of prediction (RMSEP), which describes the estimated mea-
surement error, were calculated according to
50
N	 (14)
RMSEP = -1
55	 N
where N is the number of light attenuation spectra, and y, and
y, are theoretical and experimentally determined values of
60 SO2, respectively. Relatively large values of R 2 (e.g., values
approaching unity) and relatively small values of RMSEP
indicate that the experimentally determined SO 2 values are
accurate (e.g., match the theoretical SO 2 values closely).
Simulated light attenuation spectra calculated using Equa-
65 tion (8) are shown in FIG. 6 for a series of theoretical values
of SO2 . The light attenuation spectra in FIG. 6 correspond to
a target tissue that does not scatter incident light (e.g., light
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attenuation occurs by absorption only). Simulated light
attenuation spectra calculated for a light scattering target
tissue that corresponds to a forearm of a patient are shown in
FIG. 7 for a series of theoretical values of S0 2 . In each of
FIGS. 6 and 7, a water concentration cwat of 60% and a
source-detector spacing d of 3 cm were used in the calcula-
tions.
FIG. 8 is a plot showing actual (theoretical) and estimated
(measured) values of S02, determined by fitting the four sets
of light attenuation spectra calculated using Equations (8)-
(13) to the model given by Equation (2) according to the
procedure shown in FIG. 3. The fitting algorithm used was a
Levenberg-Marquardt optimization method with initial
parameter values obtained from the sweep technique dis-
cussed above. Values of R 2 between 0.99 and 1 were obtained
for each of the four sets of attenuation spectra (e.g., for each
of the four different target tissues), with a maximum RMSEP
of less than 5% S02 . The relatively high values of R2 and
relatively low RMSEP values indicate that accurate measure-
ments of S02 in each of the four target tissues were achieved.
For comparison, the theoretical light attenuation spectra were
also fitted to Equation (2) using a DE algorithm, and the
values of the model parameters obtained from the fitting
procedure were used to calculate S02 values. The results are
shown in Table 1 below. For three of the four target tissues, the
RMSEP for S02 determined via the DE algorithm was lower
than the RMSEP for S02 determined via the Levenberg-
Marquardt algorithm.
TABLE 1
Target Tissue Type	 R^	 RMSEP (% SOz)
Non-scattering	 0.99	 1.31
Forearm scattering	 0.99	 4.10
Calf scattering	 0.99	 3.86
Intact Head scattering	 0.99	 2.81
Example 2
To simulate the early stages of hemorrhagic shock in
human patients, a test protocol that included progressively
increasing magnitudes of lower body negative pressure
(LBNP) in five human test subjects was performed. The
LBNP protocol consisted of a five minute baseline period,
followed by five minute intervals of chamber decompression
to -15, -30, -45, and -60 mm Hg, followed by additional
increments of -10 mm Hg every five minutes until either the
onset of cardiovascular collapse, or the completion of five
minutes at -100 mm Hg. Infrared reflectance spectra were
recorded continuously throughout the protocol using a fiber
optic sensor with both short-distance and long-distance
source-detector spacings. The sensor was placed on the flexor
digitorum profundus muscle of the forearm.
Oxygen saturation and oxygen tension in the muscle tissue
were calculated from light attenuation spectra generated from
the reflectance spectra using the methods disclosed above.
The reflectance spectra were corrected to remove contribu-
tions from light absorption and/or scattering by skin pigments
and fat prior to generating the light attenuation spectra. A
blood sample was withdrawn from each test subj ect in the last
minute of each stage of the LBNP protocol. Oxygen satura-
tion for each subject was measured from the blood sample
using a co-oximeter instrument, and oxygen tension was mea-
sured using a blood gas analyzer.
FIG. 9 shows the correlation between oxygen saturation
measured from withdrawn blood samples (0211b (%) blood)
20
and oxygen saturation measured via infrared reflectance mea-
surements (LAIRS S02(%)) at various stages of the LNBP
protocol for each of the five test subjects. FIG. 10 shows the
correlation between oxygen tension measured from with-
5 drawn blood samples (Venous P02) and oxygen tension mea-
sured via infrared reflectance measurements (LAIRS P0 2) dur-
ing the LNBP protocol for each of the five subj ects. In FIG. 9,
the RMSEP in S02 is about 8%, and in FIG. 10, the RMSEP
in P02 is about 3.3 mm Hg. These relatively low errors of
to prediction indicate that S02 and P02 values determined via
infrared reflectance measurements correspond accurately to
actual S02 and P02 values in target tissues. The accuracy of
the S02 and P02 values further indicates that the systems and
methods disclosed herein provide accurate and sensitive diag-
15 nosis of conditions such as hemorrhagic shock in patients.
Other Embodiments
The systems and methods disclosed herein can make use of
20 other light attenuation models (e.g., models other than Equa-
tion (2)) to determine S0 2 and other physiological quantities
such as P02 in target tissues. Three different alternative mod-
els will be discussed; other models are also possible. The
following alternative models have been investigated for accu-
25 racy by fitting sets of theoretical light attenuation spectra
generated using Equations (8)-(13), and corresponding to
four different target tissues (e.g., non-scattering tissue, fore-
arm tissue, calf tissue, and intact head tissue), to each of the
models, and calculating coefficients of determination and
3o RMSEP values for values of S02 determined for each target
tissue using each model.
Model 2
As discussed above, measured light attenuation spectra can
35 be fitted to the model given by Equation (2). Following the
fitting procedure, values of the parameters c o, c l , <L>,
cab+Mb, Cab02+Mb021 and cwat are obtained. Using the values
of these parameters, a wavelength-dependent baseline spec-
trum is calculated from a difference between the model given
40 by Equation (2) with fitted values of the parameters, and the
measured light attenuation spectra. The baseline spectrum is
calculated according to
bspect(T) 1,(T)-A,(T)	 (15)
45 where A_P (X) is the light attenuation model function given by
Equation (2) with the best-fit parameter values.
Then in a subsequent step, with fitted values of the param-
eters C O, c l , <L>, cab+Mb, Cab02+MbO2, and Cwat as initial
parameter values, the measured light attenuation spectra are
50 fitted to the model equation
A m.dea (;L) = c2 [bspect(A) + co + c i A] + ln(10) .	 (16)
W - [eHb+Mb £Hb(;L) +CHb02+MbO2 —HbO2+MbO2(;L) +ew --t(;L)1
55
In the model given by Equation (16), c 2 is a scale factor that is
varied along with the other fitting parameters. From refined
60 values of cab+Mb and cab02+Mb02 that are obtained by fitting
Equation (16) to the measured light attenuation spectra, val-
ues of S02 and P02 are calculated.
This multi-step fitting procedure first, to determine base-
line spectrum bspect(X), and second, to determine S0 2 and
65 P02 from fitted values of the parameters in Equation (16)
provides for more accurate determination of the parameters in
Equation (16), and therefore, more accurate S0 2 and P02
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3µs(d)	 (21)
d pf (d) = 2
5
A nonlinear Levenberg-Marquardt least-squares fitting
procedure was used to determine values of the various model
parameters by fitting the theoretical (e.g., simulated) light
10 attenuation spectra to the model given by Equations (I8)-
(21). Values of S0 2 were then calculated from the fitted values
of the parameters in Equation (19). Table 3 below shows R2
and RMSEP results from a comparison of experimentally
determined S02 values and theoretical S02 values. As shown
15 in the table, R2 values were 0.97 or larger for all four target
tissues, and RMSEP values were less than 10 % SOz . These
statistical measures indicate that Model 3 provided for accu-
rate determination of S02 in the target tissues.
Comparing to the results for Model 2, Model 3 appears to
20 provide slightly less accurate results on average for the test
data evaluated herein. However, for certain tissues, Model 3
may provide more accurate S0 2 determinations (e.g., com-
In this model, light attenuation by absorption and by scat- 	 pare results for intact head target tissue).
tering have similar functional forms. The model equation is 25	 TABLE 3
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values. Table 2 below shows R2 and RMSEP values calcu-
lated for each of the four different theoretical target tissues for
which light attenuation spectra were simulated using Equa-
tions (8)-(13). Values of S02 determined from fitting the
theoretical light attenuation spectra using the multi-step fit-
ting procedure discussed above were compared to the theo-
retical values of SO2 , which yielded an R2 value of 0.99 for
each of the tissues, and RMSEP values of less than 6% SOz.
The relatively large R2 values and relatively low RMSEP
values indicated that Model 2 provided accurate determina-
tion of S02 in target tissues.
TABLE 2
Target Tissue Type	 R2	 RMSEP (% S02)
Non-scattering	 0.99	 1.73
Forearm scattering	 0.99	 3.69
Calf scattering	 0.99	 4.66
Intact Head scattering	 0.99	 5.77
Model 3
Amoeea (d) = Luo (d) + µ (d)1 ' d . d pf (d)	 (17)
= Luo (d) + c, - µs(d)1 - d - d pf (d)
where µa(X) and µ (X) are wavelength-dependent absorption
and scattering coefficients of the target tissue, respectively, ci
is a constant, d is a source-detector distance, and dpf(X) is a
differential path length factor for the tissue. The scattering
coefficient µ (X) is related to the reduced scattering coeffi-
cient µ '(X) according to µs'(^)=(1-g)µs(^), where g is an
anisotropy factor that corresponds to an average cosine of the
scattering angle.
To compensate for a difference between absolute light
intensity Io(X) and the reference light intensity 1,,,(X) from a
99% reflectance standard, as discussed above, a constant term
co can be added to Equation (17) to yield a model equation
Target Tissue Type	 R2	 RMSEP (% SO2)
Non-scattering	 0.99	 1.81
Forearm scattering	 0.97	 9.37
30	 Calf scattering	 0.97	 7.09
Intact Head scattering	 0.99	 5.18
Model 4
35	 Models based on diffusion theory can also be used in the
systems and methods disclosed herein. According to diffu-
sion theory, the diffuse reflectance, R(d,X), of continuous-
wave light radiation emitted from a semi-infinite scattering
medium at a source-detector separation d larger than about 2
40 cm, is given by
1 + 2C	 µe (xM	 (22)
R(d,d)
10 (A)	 2)T 3 ^µff(d)+d^^ d2
45
where C is a constant that is independent of d and related to an
internal specular reflection parameter. The value of C
50 depends on the refractive indices of the target tissue and
surrounding medium. Values of lL ,(X) are calculated accord-
ing to
µ"-(T )— 3F'W [µ"N+µ"'N]	 (23)
The absorption coefficient µ a(X) is calculated as in Equa-
55 tion (19), and the reduced scattering coefficient µ '(X) is cal-
culated as in Equation (20). A constant term co is also added
to compensate for differences between I o (X) and I t(^), as
discussed above, so that the model light attenuation equation
two constants, c z and c3 , according to	 is
60
µs (T)=C2+C1	(20)
During the fitting procedure, constraints are imposed on c 3 so	 Amoee,(d, l) = ln( ,O (') = -lnR(d, l) + co	 (24)
that c3<0.
The differential path length factor is expressed as a func- 65
tion of the reduced scattering coefficient and the absorption 	 A two-stage nonlinear least-squares fitting procedure was
coefficient according to	 used to determine parameters of the model given by Equa-
A moeea (d) = [µ,(;L) + y (d)1 L . d pf (d) + C o 	 (18)
= ^to(d)+ c t -µs(d)1-L.dpf(d)+co
In Equation (18), the absorption coefficient µ a(X) is related to
concentrations of absorbing components in the target tissue
according to
Il,(k)—CHI.EHb(k)+CH102+MbO2EHb02(k)+
C_E_(k)	 (19)
The reduced scattering coefficient µ '(X) is a function of
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tions (19), (20), and (22)-(24) by fitting the equations to the
theoretical data for each of the four different target tissues. In
a first stage of the fitting procedure, prior to performing a fit of
all of the model parameters to the data, a good initial value of
the parameter C was obtained by using the sweep method.
Values of the parameters co, c2, c3, CFIb+Mb, c11b02+Mb02, and
cwat, were held constant, and the theoretical light attenuation
spectra were fitted to Equation (24), allowing only C to vary
among the model parameters. Fitting the data to Equation
(24) included minimizing a sum of squared differences, x2
between the model and the theoretical data, as discussed in
connection with Equation (4). The value of C obtained from
the sweep method corresponded to a good estimate for
parameter C.
In the second stage of the fitting procedure, the value of C
determined in the first stage was used as the final value of C in
Equation (22) (e.g., fixed as a constant), and the theoretical
light attenuation spectra were again fitted to Equation (24),
permitting each of the parameters c o, c21 C31 C Ub+Mb, CUb02+
Mb02, and cwat to vary during fitting. In this manner, accurate
values of the six parameters were obtained, and S0 2 in each of
the target tissues was calculated based on the values of c,,b+Mb
and C,1b02+Mb02 from the fitting procedure. Table 4 below
shows R2 and RMSEP results from a comparison of experi-
mentally determined S02 values and theoretical S02 values.
As shown in the table, R2 values were 0.99 for all four target
tissues, and RMSEP values were less than 7% S0 2 . These
statistical measures indicate that Model 4 provided for accu-
rate determination of S02 in the four target tissues. Based on
the R2 and RMSEP values, the results for each of Models 2, 3,
and 4 achieved comparable accuracy.
TABLE 4
Target Tissue Type	 R^	 RMSEP (% SOz)
Non-scattering	 0.99	 1.52
Forearm scattering	 0.99	 5.35
Calf scattering	 0.99	 6.63
Intact Head scattering	 0.99	 5.99
It is to be understood that while the invention has been
described in conjunction with the detailed description
thereof, the foregoing description is intended to illustrate and
not limit the scope of the invention, which is defined by the
scope of the appended claims. Other aspects, advantages, and
modifications are within the scope of the following claims.
What is claimed is:
1. A method for calculating oxygen saturation in a target
tissue, the method comprising:
directing incident radiation from a source to a target tissue
and determining reflectance spectra of the target tissue
with a detector by measuring intensities of reflected
radiation from the target tissue at a plurality of radiation
wavelengths;
correcting the measured intensities of the reflectance spec-
tra to reduce contributions thereto from skin and fat
layers through which the incident radiation propagates;
determining oxygen saturation in the target tissue based on
the corrected reflectance spectra; and
outputting the determined value of oxygen saturation,
wherein determining reflectance spectra of the target tissue
comprises:
measuring, at a first source-detector spacing, a first reflec-
tance spectrum from the target tissue that comprises a
first weighting of contributions from the target tissue and
from the skin and fat layers, and measuring, at a second
source-detector spacing different from the first source-
24
detector spacing, a second reflectance spectrum from the
target tissue that comprises a second weighting of con-
tributions from the target tissue and from the skin and fat
layers different from the first weighting; and
5	 wherein correcting the measured intensities of the reflec-
tance spectra comprises:
correcting the measured intensities of the first reflectance
spectrum based on the measured intensities of the sec-
ond reflectance spectrum.
10 2. The method of claim 1, wherein determining oxygen
saturation comprises determining light attenuation spectra
from the corrected reflectance spectra, and calculating oxy-
gen saturation based on concentrations of oxygenated and
deoxygenated heme in the target tissue that are derived from
15 the light attenuation spectra, wherein heme comprises hemo-
globin and myoglobin in the target tissue.
3. The method of claim 2, wherein the concentrations of
oxygenated and deoxygenated heme are derived from the
light attenuation spectra by fitting the light attenuation spec-
20 tra to a model light attenuation equation.
4. The method of claim 3, wherein the light attenuation
equation comprises a Beer's Law equation comprising terms
that correspond to incident light absorption by oxygenated
25 heme, deoxygenated heme, and water in the target tissue.
5. The method of claim 4, wherein the light attenuation
equation comprises a series expansion of light attenuation in
a plurality of terms that correspond to Beer's Law absorption
terms.
30 6. The method of claim 5, wherein the series expansion of
light attenuation comprises a Taylor series expansion of light
attenuation.
7. The method of claim 4, wherein the light attenuation
equation further comprises a baseline function derived from a
35 difference between light attenuation values determined from
the light attenuation equation and the light attenuation spec-
tra.
8. The method of claim 4, wherein the light attenuation
equation further comprises a differential path length factor
40 that varies directly with a scattering coefficient of the target
tissue and inversely with an absorption coefficient of the
target tissue.
9. The method of claim 3, wherein the light attenuation
equation comprises a term that varies linearly with a wave-
45 length of the incident light, the term having a functional form
aX where a is a constant and X is the wavelength of the incident
light.
10. The method of claim 9, wherein the value of a is
constrained during fitting so that a assumes only values that
So are less than or equal to zero.
11. The method of claim 3, wherein the light attenuation
equation comprises a constant term independent of a wave-
length of the incident light.
55 12. The method of claim 3, wherein fitting the light attenu-
ation spectra to a model comprises performing a two-stage
fitting procedure wherein, in a first stage, initial values of one
or more model parameters are determined, and in a second
stage, the light attenuation spectra are fitted to the model,
60 wherein the model comprises the initial parameter values
determined in the first stage.
13. The method of claim 12, wherein the light attenuation
spectra are fitted to the model by minimizing a sum of squared
differences between the light attenuation spectra and light
65 attenuation values determined from the model.
14. The method of claim 3, wherein the fitting is performed
automatically by a processor.
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15. The method of claim 3, wherein the light attenuation
equation comprises a diffuse reflectance equation derived
from a radiation diffusion model of incident light in the target
tissue.
16. The method of claim 2, further comprising assessing a 5
level of vasoconstriction in a patient based on a measurement
of total hemoglobin in a target tissue of the patient, wherein
total hemoglobin is determined based on the concentrations
of oxygenated and deoxygenated heme in the target tissue.
17. The method of claim 1, wherein correcting the mea- 10
sured intensities of the first reflectance spectrum comprises
reducing contributions from the skin and fat layers to the first
reflectance spectrum based on the measured intensities of the
second reflectance spectrum.
18. The method of claim 1, further comprising determining 15
oxygen tension in the target tissue based on oxygen saturation
in the target tissue.
19. The method of claim 1, wherein the target tissue is
within a human.
20. The method of claim 19, wherein the plurality of wave- 20
lengths comprises wavelengths from 725 mn to 880 mu.
21. The method of claim 1, wherein the target tissue is
within an animal.
22. The method of claim 1, wherein the plurality of wave-
lengths comprises at least 100 wavelengths or more. 	 25
23. The method of claim 1, wherein the plurality of wave-
lengths comprises wavelengths from 700 mn to 1000 mu.
24. The method of claim 1, wherein the target tissue is a
muscle tissue.
25. A method of monitoring blood volume in a patient, the 30
method comprising:
directing incident radiation from a source to a target tissue
of the patient and determining reflectance spectra of the
target tissue with a detector by measuring intensities of
reflected radiation from the target tissue at a plurality of 35
wavelengths;
correcting the measured intensities of the reflectance spec-
tra to reduce contributions thereto from skin and fat
layers through which the incident radiation propagates; 40determining total heme concentration in the target tissue
based on the corrected reflectance spectra;
assessing a blood volume in the patient based on the total
heme concentration; and
outputting the assessed blood volume, 	 45
wherein determining reflectance spectra of the target tissue
comprises:
measuring, at a first source-detector spacing, a first reflec-
tance spectrum from the target tissue that comprises a
first weighting of contributions from the target tissue and 50
from the skin and fat layers, and measuring, at a second
source-detector spacing different from the first source-
detector spacing, a second reflectance spectrum from the
target tissue that comprises a second weighting of con-
tributions from the target tissue and from the skin and fat 55
layers different from the first weighting; and
wherein correcting the measured intensities of the reflec-
tance spectra comprises:
correcting the measured intensities of the first reflectance
spectrum based on the measured intensities of the sec- 60
and reflectance spectrum.
26. The method of claim 25, further comprising assessing
a stage of progress of at least one of hemorrhage, sepsis, heart
disease, and diabetes in the patient based on the assessed
blood volume.	 65
27. A method for calculating oxygen saturation in a target
tissue, the method comprising:
26
directing incident radiation from a source to a target tissue
and determining reflectance spectra of the target tissue
with a detector by measuring intensities of reflected
radiation from the target tissue at a plurality of radiation
wavelengths;
determining light attenuation spectra of the target tissue
from the reflectance spectra, and fitting the light attenu-
ation spectra to a model light attenuation equation;
determining oxygen saturation in the target tissue based on
the fitting of the light attenuation spectra; and
outputting the determined value of oxygen saturation,
wherein fitting the light attenuation spectra to a model
comprises performing a two-stage fitting procedure
wherein, in a first stage, initial values of one or more
model parameters are determined, and in a second stage,
the light attenuation spectra are fitted to the model,
wherein the model comprises the initial parameter val-
ues determined in the first stage; and
wherein determining reflectance spectra of the target tissue
comprises:
measuring, at a first source-detector spacing, a first reflec-
tance spectrum from the target tissue that comprises a
first weighting of contributions from the target tissue and
from skin and fat layers through which the incident
radiation passes, and measuring, at a second source-
detector spacing different from the first source-detector
spacing, a second reflectance spectrum from the target
tissue that comprises a second weighting of contribu-
tions from the target tissue and from the skin and fat
layers different from the first weighting; and
correcting the measured intensities of the first reflectance
spectrum based on the measured intensities of the sec-
ond reflectance spectrum.
28. The method of claim 27, wherein the model comprises
a term having a functional form aX and wherein the value of
a is constrained during the fitting to be less than or equal to
zero.
29. A system, comprising:
a light source configured to direct incident radiation to a
target tissue;
a detector; and
a processor coupled to the detector and configured to:
determine reflectance spectra of the target tissue;
correct the reflectance spectra to reduce contributions
thereto from skin and fat layers through which the inci-
dent radiation propagates; and
determine oxygen saturation in the target tissue based on
the corrected reflectance spectra,
wherein the processor is configured to determine the
reflectance spectra by:
measuring, at a first source-detector spacing, a first reflec-
tance spectrum from the target tissue that comprises a
first weighting of contributions from the target tissue and
from skin and fat layers through which the incident
radiation passes, and measuring, at a second source-
detector spacing different from the first source detector
spacing, a second reflectance spectrum from the target
tissue that comprises a second weighting of contribu-
tions from the target tissue and from the skin and fat
layers different from the first weighting; and
wherein the processor is configured to correct the reflec-
tance spectra by:
correcting the measured intensities of the first reflectance
spectrum based on the measured intensities of the sec-
ond reflectance spectrum.
30. The system of claim 29, wherein the processor is con-
figured to determine reflectance spectra of the target tissue by
36. The system of claim 29, wherein the first and second
10 source detector distances correspond to first and second
radiation paths between the light source and the detector, and
each of the first and second radiation paths comprises an
optical fiber.
15 37. The system of claim 29, wherein the processor is fur-
ther configured to determine oxygen tension in the target
tissue from oxygen saturation.
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directing the detector to measure intensities of reflected radia-
tion from the target tissue at a plurality of radiation wave-
lengths.
31. The system of claim 29, wherein the processor is con-
figured to determine oxygen saturation by calculating light
attenuation spectra from the corrected reflectance spectra,
and calculating oxygen saturation based on concentrations of
oxygenated and deoxygenated heme in the target tissue that
are derived from the light attenuation spectra, wherein heme
comprises hemoglobin and myoglobin in the target tissue.
32. The system of claim 31, wherein the processor is con-
figured to derive the concentrations of oxygenated and deoxy-
genated heme in the target tissue by fitting the light attenua-
tion spectra to a model light attenuation equation.
33. The system of claim 32, wherein the model light attenu-
ation equation comprises a Beer's Law equation comprising
terms that correspond to absorption of incident radiation by
oxygenated heme, deoxygenated heme, and water in the tar-
get tissue.
28
34. The system of claim 31, wherein the processor is fur-
ther configured to determine total heme concentration in the
target tissue from the concentrations of oxygenated and
deoxygenated heme in the target tissue.
35. The system of claim 34, wherein the processor is fur-
ther configured to assess a blood volume in the target tissue
based on the total heme concentration.
